Risk Factors for Progression of and Treatment Options for NAFLD in Children

Size: px
Start display at page:

Download "Risk Factors for Progression of and Treatment Options for NAFLD in Children"

Transcription

1 REVIEW Risk Factors for Progression of and Treatment Options for NAFLD in Children Phillipp Hartmann, M.D.,* and Bernd Schnabl, M.D., Nonalcoholic fatty liver disease (NAFLD) is a common disease and can affect both adults and children. It is defined as a long-standing hepatic steatosis that is not due to genetic or metabolic disorders, infections, side effects of medication, alcohol consumption, or malnutrition. Pediatric NAFLD occurs in children 18 years or younger. Alanine aminotransferase (ALT) cutoffs for the diagnosis of NAFLD have been determined to be 22 mg/ dl for girls and 26 mg/dl for boys in the United States. NAFLD is linked to obesity and insulin resistance, but also to dyslipidemia with high triglyceride, high low-density lipoprotein (LDL), and low high-density lipoprotein (HDL) cholesterol levels. NAFLD can be subgrouped into several entities, with the main pathologies being nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and end-stage cirrhosis, which can be associated with similar complications in children as seen in adults (see Table 1 for definitions). 1 This review highlights several risk factors for NAFLD progression to NASH in children, examines novel treatment options, and investigates the role of the intestinal microbiome in NAFLD. DEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH NAFLD AND PROGRESSION TO NASH IN CHILDREN Several factors determine the risk for NAFLD progression to NASH in children (Fig. 1). Demographics. Pediatric NAFLD is more likely to be present in boys than in girls and more likely in adolescents than in toddlers. The risk for NAFLD is directly proportional to the body mass index (BMI), with obese children being most at risk for NAFLD. The Hispanic population has a higher risk for NAFLD than Asian or white children. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; EtOH, ethanol; LPS, lipopolysaccharide; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PNPLA3, patatin-like phospholipase domain-containing 3. From the Departments of *Pediatrics and Medicine, University of California San Diego, La Jolla, CA, and Department of Medicine, VA San Diego Healthcare System, San Diego, CA. This study was supported by National Institutes of Health grant R01 AA Potential conflict of interest: Nothing to report. Received 31 August 2017; accepted 13 November 2017 View this article online at wileyonlinelibrary.com VC 2018 by the American Association for the Study of Liver Diseases 11 CLINICAL LIVER DISEASE, VOL 11, NO 1, JANUARY 2018 An Official Learning Resource of AASLD

2 TABLE 1. SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE Type NAFLD NAFL NASH Cirrhosis Definition Wide spectrum of conditions, all with long-standing hepatic steatosis, not due to genetic or metabolic disorders, infections, side effects of medication, alcohol consumption, or malnutrition At least 5% of hepatic fat by imaging or histology, without inflammation, with or without fibrosis Hepatic steatosis and liver inflammation ( -hepatitis ), with or without fibrosis End-stage liver disease in the setting of NAFLD Spectrum of Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD encompasses non-alcoholic fatty liver (NAFL) with 5% fat content; non-alcoholic steatohepatitis (NASH) with fatty liver and liver inflammation (both entities with or without fibrosis); and NAFLD with cirrhosis which represents hepatic end-stage disease. Based on data from Vos et al. 1 Black children are least likely to experience NAFLD (Table 2). 2 Hispanic children have also been found to be more at risk for NASH. Interestingly, a single-nucleotide polymorphism in the patatin-like phospholipase domaincontaining 3 (PNPLA3) gene (SN rs C>G), involved in lipid metabolism, is more common in Hispanic individuals and has been independently associated with NAFLD and NASH. 3 Diet. Fructose consumption has been associated with NAFLD severity in both cross-sectional and interventional studies. There is evidence that fructose consumption was independently associated with NASH in obese children with NAFLD; it also showed that fructose intake was independently linked to hyperuricemia. 4 An intervention with a low-fructose diet in pediatric NAFLD demonstrated that fructose intake correlated strongly with plasma ALT, aspartate aminotransferase (AST), and insulin resistance, independently of weight loss. 5 Furthermore, a recent study showed that a 9-day-long fructose restriction led to significantly decreased liver fat, visceral fat, and hepatic de novo lipogenesis in obese children. 6 Metabolic Syndrome. Individual features of metabolic syndrome, in particular central obesity and insulin resistance, were found to be associated with severity of NAFLD in children. 7 In addition, dyslipidemia, hyperuricemia, prediabetes, and diabetes were associated with a higher risk for pediatric NASH. 4,8 TABLE 2. PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN CHILDREN Variable Group Prevalence of NAFLD (%) FIG 1 Risk Factors for Progression of Non-Alcoholic Fatty Liver Disease (NAFLD) to Non-Alcoholic Steatohepatitis (NASH) in Children. Multiple risk factors for progression to NASH have been identified, such as diet (e.g., fructose) and metabolic factors, for example, metabolic syndrome, in particular dyslipidemia, hyperuricemia, diabetes mellitus type 2, and possibly an increased BMI z score. Specific ethnicities and genetic setups have been found to be more susceptible to NASH, for example, Hispanic subjects and subjects with polymorphisms in the PNPLA3 gene. Other risk factors for the progression to NASH, such as physical inactivity, older pediatric age, or high birth weight, are conceivable or have been suggested by single studies, but robust scientific evidence is still lacking. Abbreviations: NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PNPLA3, patatin-like phospholipase domain-containing 3. Gender Male 11.1 Female 7.9 Age 2-4 years years years years 17.3 Ethnicity Black 1.5 White 8.6 Asian 10.2 Hispanic 11.8 BMI 5% 0 >5% to < 85% 5 85% to < 95% 16 95% 38 Based on data from Schwimmer et al CLINICAL LIVER DISEASE, VOL 11, NO 1, JANUARY 2018 An Official Learning Resource of AASLD

3 FIG 2 Simplified model of intestinal Stages in the development of nonalcoholic fatty liver disease (NAFLD) and ways probiotics can intervene. Adverse environmental, metabolic and genetic factors such as diet rich in fat or fructose can cause intestinal dysbiosis with reduction of beneficial bacteria and increase of deleterious bacteria. Dysbiosis results in increased intestinal permeability, or leaky gut, by disruption of tight junction proteins such as zonula occludens-1 and occludin. Associated metabolic changes in the bacteria lead to - amongst others - depletion of choline (which is metabolized to trimethylamine [TMA]), and production of ethanol (EtOH). EtOH and microbial products, e.g. lipopolysaccharides (LPS), translocate from the intestine into the blood circulation and travel to the liver. In the liver, choline deficiency promotes steatosis, and EtOH and LPS cause more liver inflammation and finally NAFLD/nonalcoholic steatohepatitis (NASH). Probiotics (living non-pathogenic microorganisms such as Lactobacilli and Bifidobacteria that have a favorable impact on the host) work on several levels. They attenuate intestinal dysbiosis and metabolic changes, and ameliorate the leaky gut by preventing inflammation and apoptosis of the enterocytes, and by inducing tight junction proteins. Probiotics thereby decrease translocation of bacterial products and metabolites into the blood stream, which eventually alleviates liver injury. Abbreviations: EtOH, ethanol; LPS, lipopolysaccharide; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; TMA, trimethylamine. NOVEL TREATMENTS Currently, pediatric NAFLD is mostly managed by lifestyle modifications including a healthy, well-balanced diet without sugar-sweetened beverages, daily moderateto high-intensity exercise, and less than 2 hours of screen time per day. 1 Only a relatively small number of pediatric drug trials have been conducted for NAFLD/NASH and have thus far focused on hepatic lipid metabolism, insulin resistance, and/or liver inflammation/oxidative stress. A few studies have shown that vitamin E (with lifestyle interventions) results in an improvement of ALT levels in pediatric patients with NAFLD similar to controls. One study demonstrated that high-dose vitamin E over 2 years resulted in significantly better NAFLD activity scores and greater resolution of NASH when compared with controls despite similar ALT levels. 1 A few short-term studies with probiotics, or living nonpathogenic microorganisms such as Lactobacilli and Bifidobacteria that have a favorable 13 CLINICAL LIVER DISEASE, VOL 11, NO 1, JANUARY 2018 An Official Learning Resource of AASLD

4 impact on the host, 9 showed improvement of pediatric NAFLD/NASH either with regard to ALT levels or hepatic steatosis. Fifty-two weeks of cysteamine bitartrate delayed release (CBDR), a potent antioxidant, led to significant reductions in serum aminotransferase levels and lobular inflammation, but not to significant improvement of overall histological markers of NAFLD compared with placebo. Several studies demonstrated that omega-3 fatty acids (docosahexaenoic acid [DHA]/eicosapentaenoic acid [EPA]) ameliorate liver steatosis on ultrasound and insulin sensitivity, improve liver and visceral fat, fasting insulin and/or lipid serum levels relative to placebo; however only one showed modest improvement of ALT levels. and improve liver and visceral fat, fasting insulin, and/or. 1 In summary, several drugs have been tested in pediatric NAFLD/NASH trials and resulted in some improvement with regard to systemic ALT levels, hepatic steatosis on ultrasound, and/or liver histology. However, most have not led to significantly better outcomes in relation to placebo/lifestyle intervention only. ASSOCIATION BETWEEN THE INTESTINAL MICROBIOME AND NAFLD Children with NASH harbor significantly higher intestinal amounts of the gram-negative bacteria Proteobacteria, Enterobacteriaceae, and ethanol (EtOH)-producing Escherichia than healthy children. 10 Intriguingly, children with NASH have also been shown to have significantly higher serum levels of EtOH, which can promote gut permeability. 9,10 In addition, they harbor fewer of the beneficial Bifidobacteria than healthy children. 10 This is an example of intestinal dysbiosis, or a microbial imbalance with its associated deleterious effects on the colonized host. 9 Dysbiosis is linked to translocation of bacterial products, for example, lipopolysaccharides (LPS) from gram-negative bacteria, into the bloodstream. The latter is facilitated by increased intestinal permeability ( leaky gut ) and is a hallmark event in the development of NAFLD/NASH, with subsequent hepatic steatosis and inflammation. 11 Antibiotics, prebiotics (complex carbohydrates nondegradable by humans promoting the growth of beneficial bacteria), and probiotics are aiming at preventing this translocation 9 (for more details, refer to Fig. 2, as well as Hartmann et al. 9 and Schnabl and Brenner 11 ). Given the likelihood that resistant pathogenic bacteria could be selected, no antibiotic trials for pediatric NAFLD have been conducted. Despite promising results from studies with rodents (using oligo-fructose or lactulose), clinical trials for pediatric NAFLD/NASH with prebiotics have not been carried out yet. A few encouraging interventions with probiotics in children with liver disease have been completed (see above). However, longer trials with larger sample sizes are necessary to confirm these results and possibly demonstrate robust improvement of both liver steatosis and ALT levels in pediatric NAFLD before routine use can be recommended. In conclusion, lifestyle intervention including diet and physical exercise regimens remains the most important intervention for NAFLD for now. However, our understanding of the role of the intestinal microbiome in the development of NAFLD/NASH is evolving and supports a potential role of probiotics and possibly prebiotics in pediatric NAFLD/NASH, also in light of a favorable side effect profile. CORRESPONDENCE Phillipp Hartmann, M.D., Department of Pediatrics, University of California San Diego, MC0063, 9500 Gilman Drive, La Jolla, CA Telephone: ; FAX: ; phhartmann@ucsd.edu REFERENCES 1) Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64: ) Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: ) Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013;19: ) Mosca A, Nobili V, De Vito R, Crudele A, Scorletti E, Villani A, et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol 2017;66: ) Mager DR, Iniguez IR, Gilmour S, Yap J. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD). JPEN J Parenter Enteral Nutr 2015;39: CLINICAL LIVER DISEASE, VOL 11, NO 1, JANUARY 2018 An Official Learning Resource of AASLD

5 6) Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 2017;153: ) Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TT, Rosenthal P, et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 2010;105: ) Newton KP, Hou J, Crimmins NA, Lavine JE, Barlow SE, Xanthakos SA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 2016;170:e ) Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol 2012;3: ) Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57: ) Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014;146: CLINICAL LIVER DISEASE, VOL 11, NO 1, JANUARY 2018 An Official Learning Resource of AASLD

CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health

CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver

More information

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based

More information

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem

More information

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011 Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled

More information

Improving Access to Quality Medical Care Webinar Series

Improving Access to Quality Medical Care Webinar Series Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX

More information

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic

More information

NAFLD/NASH in Sub- Saharan Africa

NAFLD/NASH in Sub- Saharan Africa NAFLD/NASH in Sub- Saharan Africa Corné Kruger Gastroenterologist Durbanville Mediclinic Cape Town Liver Interest group meeting: Cape Town 2015 Introduction NAFLD is the most common liver disease disease

More information

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012 NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat

More information

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion

More information

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the

More information

Disclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH?

Disclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH? Disclosures I have the following relationships to disclose: Ethicon Endo Surgery Inc. Galectin Therapeutics Synageva Biopharma Raptor Pharmaceuticals I will be discussing off label use of medications in

More information

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary

More information

HOW THE MICROBIOME AFFECTS OUR HEALTH

HOW THE MICROBIOME AFFECTS OUR HEALTH HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins

More information

Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic

Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic NASH and NAFLD Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic David E. Bernstein xiii Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

More information

The effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease

The effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes

More information

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Diseases to Watch Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) - Prevalence and Symptoms - Risk Factors and Potential treatments - Target identification for NASH Robert

More information

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?

WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:

More information

NONALCOHOLIC FATTY LIVER DISEASE

NONALCOHOLIC FATTY LIVER DISEASE NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis

More information

Challenges in the Diagnosis of Steatohepatitis

Challenges in the Diagnosis of Steatohepatitis The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST

MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST HUMAN MICROBIOM 10 Billion bacterias are building a 1,5 2 kg heavy human microbiom It is located mainly in the human gut There is a intestinal controlled

More information

NAFLD AND TYPE 2 DIABETES

NAFLD AND TYPE 2 DIABETES NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213

More information

NASH PROGRESS IN THE LAST DECADE

NASH PROGRESS IN THE LAST DECADE PROGRESS IN THE LAST DECADE Mitchell L. Shiffman, MD, FACG Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need A GLOBAL HEALTH PROBLEM Nigeria Australia Spain

More information

Fast-food, Fatty liver, & Insulin Resistance. Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna

Fast-food, Fatty liver, & Insulin Resistance. Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna Fast-food, Fatty liver, & Insulin Resistance Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna Supersize Me Unhealthy Effects of Fast Food After consuming three meals a day

More information

Therapeutic targets and the management of NASH

Therapeutic targets and the management of NASH Therapeutic targets and the management of NASH Joo Hyun Sohn, MD. Professor of Medicine, College of Medicine, Hanyang University Division of Gastroenterology and Hepatology Hanyang University Guri Hospital

More information

FoodGate: The break-in, cover-up, and aftermath. Robert H. Lustig, M.D., M.S.L. Cristin Kearns, D.D.S., M.B.A. Laura Schmidt, Ph.D., M.P.H., L.C.S.W.

FoodGate: The break-in, cover-up, and aftermath. Robert H. Lustig, M.D., M.S.L. Cristin Kearns, D.D.S., M.B.A. Laura Schmidt, Ph.D., M.P.H., L.C.S.W. FoodGate: The break-in, cover-up, and aftermath Robert H. Lustig, M.D., M.S.L. Cristin Kearns, D.D.S., M.B.A. Laura Schmidt, Ph.D., M.P.H., L.C.S.W. Osher Mini Med School for the Public, Mar 6, 2018 Decrease

More information

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal

More information

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general

More information

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:

More information

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined

More information

Disclosures. Overview. Case 1. Common Bile Duct Sizes 10/14/2016. General GI + Advanced Endoscopy: NAFLD/Stones/Pancreatitis

Disclosures. Overview. Case 1. Common Bile Duct Sizes 10/14/2016. General GI + Advanced Endoscopy: NAFLD/Stones/Pancreatitis Disclosures General GI + Advanced Endoscopy: NAFLD/Stones/Pancreatitis 123 Blank Blank, LLC Aldo Maspons, MD Assistant Professor Director of Endoscopy Department of Pediatrics Texas Tech University Health

More information

METABOLIC SYNDROME AND HCV: FROM HCV

METABOLIC SYNDROME AND HCV: FROM HCV METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,

More information

NAFLD & NASH: Russian perspective

NAFLD & NASH: Russian perspective NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

Fatty liver disease: What do we know?

Fatty liver disease: What do we know? Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty

More information

Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희

Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희 Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희 Introduction Unique characteristics of Fructose Metabolism Mechanism for Fructose-Induced Insulin Resistance Epidemiological Studies

More information

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-

More information

American Journal of Oral Medicine and Radiology

American Journal of Oral Medicine and Radiology American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION

More information

PREVALENCE OF NAFLD & NASH

PREVALENCE OF NAFLD & NASH - - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)

More information

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways Department of Gastroenterology, Endocrinology & Metabolism Medical University Innsbruck Herbert Tilg Nothing to disclose Fig.

More information

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto

More information

Effects of probiotics in the treatment of alcoholic hepatitis: randomized controlled multicenter study

Effects of probiotics in the treatment of alcoholic hepatitis: randomized controlled multicenter study Effects of probiotics in the treatment of alcoholic hepatitis: randomized controlled multicenter study Lactobacillus subtilis/streptococcus faecium Lactobacillus rhamnosus R0011/acidophilus R0052 Ki Tae

More information

Health Benefits of Prebiotic Dietary Fiber

Health Benefits of Prebiotic Dietary Fiber Health Benefits of Prebiotic Dietary Fiber JENNIFER ERICKSON, PhD, RD Objectives Provide some background on dietary fiber To define the term "prebiotic dietary fiber" To discuss potential health effects

More information

At Least 1 in 5 Patients in Your Practice Have Fatty Liver

At Least 1 in 5 Patients in Your Practice Have Fatty Liver At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease

More information

Lipid and Bile Acids as NAFLD- Related Biomarkers

Lipid and Bile Acids as NAFLD- Related Biomarkers Lipid and Bile Acids as NAFLD- Related Biomarkers Puneet Puri, MBBS, MD Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University, Richmond, VA 1st International Workshop

More information

Paediatric Non-Alcoholic Fatty Liver Disease (NAFLD) CWN Spearman

Paediatric Non-Alcoholic Fatty Liver Disease (NAFLD) CWN Spearman Paediatric Non-Alcoholic Fatty Liver Disease (NAFLD) CWN Spearman Division of Hepatology Department of Medicine UCT Medical School Non-Alcoholic Fatty Liver Disease Outline of Talk Epidemiology Natural

More information

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics

More information

The role of intestinal microbiota in metabolic disease-a novel therapeutic target.

The role of intestinal microbiota in metabolic disease-a novel therapeutic target. Michael Connolly Department of Food Biosciences, The University of Reading The role of intestinal microbiota in metabolic disease-a novel therapeutic target. University of Reading 2008 www.reading.ac.uk

More information

Health relationship: Reduction of post-prandial glycaemic responses

Health relationship: Reduction of post-prandial glycaemic responses TO European Food Safety Authority Via Carlo Magno 1A 43126 Parma ITALY complaints@efsa.europa.eu RE: Health claim ID 558 relating to fructose Prague, 27th September 2018 Dear Sirs, We refer to the above

More information

Learning Objectives. Disclosures. Self Assessment Questions. Background

Learning Objectives. Disclosures. Self Assessment Questions. Background Association of Hyperuricemia with Liver Dysfunction amongst Adults with Metabolic Disorders in the United States: A Cross Sectional Study Disclosures Dr. Prashant Sakharkar and Dr. Subrata Deb declare(s)

More information

Metabolic and clinical aspects of sugar, fructose, soft drinks Dr. Shira Zelber-Sagi School of Public Health, Faculty of Social Welfare and Health

Metabolic and clinical aspects of sugar, fructose, soft drinks Dr. Shira Zelber-Sagi School of Public Health, Faculty of Social Welfare and Health Metabolic and clinical aspects of sugar, fructose, soft drinks Dr. Shira Zelber-Sagi School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa Department of Gastroenterology

More information

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient

More information

Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar

Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore

More information

Disclosures. Outline. Nothing to disclose. Dysbiosis and the gut barrier. Endotoxemia and the liver. Impact of products of bacterial metabolism

Disclosures. Outline. Nothing to disclose. Dysbiosis and the gut barrier. Endotoxemia and the liver. Impact of products of bacterial metabolism Disclosures Nothing to disclose Outline Dysbiosis and the gut barrier Endotoxemia and the liver Impact of products of bacterial metabolism 1 Dysbiosis in obesity Obesity: Dysbiosis, shown in multiple settings

More information

Microbiome and liver diseases

Microbiome and liver diseases Klinik und Poliklinik für Innere Medizin I Microbiome and liver diseases Bernd Schnabl, M.D. Department of Medicine I have no financial relationship relevant to my presentation AND my presentation does

More information

Case Presentation. Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010

Case Presentation. Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010 Case Presentation Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010 Case HPI: 4 yo female with PMHx of obesity sent to ED from clinic with BS of 353. Pt. has had polyuria for the past

More information

«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin

«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin «STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic

More information

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes

More information

Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease

Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease Liver International ISSN 1478-3223 METABOLIC AND STEATOHEPATITIS Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease Hellan K. Kwon 1, Joel K. Greenson

More information

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty

More information

What is the evidence that dietary components can act on the microbiome and influence health?

What is the evidence that dietary components can act on the microbiome and influence health? What is the evidence that dietary components can act on the microbiome and influence health? Kristin Verbeke Translational Research in Gastrointestinal Disorders KU Leuven, Leuven, Belgium Diet? health

More information

FIBOFIT IS Water soluble fiber

FIBOFIT IS Water soluble fiber FIBOFIT IS Water soluble fiber Table of nutritional value Per Serving 8 g (1Sachet) 100 g %W/W Wheat Dextrin 8g 100 g 100 % Energy 0.096 kcal Fats & Its Derinatives 0.008 g 0.1 g Protein 0.008 g 0.1 g

More information

Conflicts of Interest in the last 12 months

Conflicts of Interest in the last 12 months STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last

More information

The classical metabolic work-up, approved by the Ethics Committee of the Antwerp

The classical metabolic work-up, approved by the Ethics Committee of the Antwerp SUPPLEMENTARY MATERIALS METHODS Metabolic work-up The classical metabolic work-up, approved by the Ethics Committee of the Antwerp University Hospital and requiring written informed consent, included a

More information

Prevalence of non-alcoholic fatty liver disease among obese children in North Kerala, India

Prevalence of non-alcoholic fatty liver disease among obese children in North Kerala, India International Journal of Contemporary Pediatrics Reetha G et al. Int J Contemp Pediatr. 2017 May;4(3):1051-1055 http://www.ijpediatrics.com pissn 2349-3283 eissn 2349-3291 Original Research Article DOI:

More information

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis

More information

Non-alcoholic fatty liver disease: a new epidemic in children

Non-alcoholic fatty liver disease: a new epidemic in children Special article Arch Argent Pediatr 2016;114(6):563-569 / 563 Non-alcoholic fatty liver disease: a new epidemic in children Mirta Ciocca, M.D., a Margarita Ramonet, M.D., b and Fernando Álvarez, M.D. c

More information

NASH Bench to Bedside

NASH Bench to Bedside NASH Bench to Bedside October 2006 Anna Mae Diehl, M.D. Gastroenterology Division Duke University NonAlcoholic Fatty Liver Disease Common ~1/4-1/3 1/3 US adults Outcome highly variable Course indolent

More information

The Gut Microbiome: 101 Justin Carlson University of Minnesota

The Gut Microbiome: 101 Justin Carlson University of Minnesota The Gut Microbiome: 101 Justin Carlson University of Minnesota Where are we now? 360 B.C. 2003 Human Gut Microbes Associated With Obesity Ley et al., Nature. 2006. Consumer Driven Science For Better of

More information

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H. U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,

More information

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic

More information

Bibliografia Microbiota

Bibliografia Microbiota Bibliografia Microbiota Systematic Review: Gut Microbiota in Fecal Samples and Detection of Colorectal Neoplasms. The role of the intestinal microbiome in ocular inflammatory disease. The gut microbiome

More information

Mark Manary MD. International Symposium on Understanding Moderate Malnutrition in Children for Effective Interventions

Mark Manary MD. International Symposium on Understanding Moderate Malnutrition in Children for Effective Interventions Possible role of the microbiome in the development of acute malnutrition and implications for food-based strategies to prevent and treat acute malnutrition International Symposium on Understanding Moderate

More information

The Role of the Gut Microbiota and Probiotics in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

The Role of the Gut Microbiota and Probiotics in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) The Role of the Gut Microbiota and Probiotics in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Dr Mayur R Joshi MBBS, BSc, AICSM Pharmaceutical Physician As more research

More information

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Abetalipoproteinemia NASH and, 537 Acquired errors of metabolism NASH and, 536 537 Amiodarone steatohepatitis due to, 527 Anticonvulsant mood

More information

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for

More information

We are being killed by fructose by Robert Harrison Black

We are being killed by fructose by Robert Harrison Black We are being killed by fructose by Robert Harrison Black bob@life401.com Executive summary: We are having an epidemic of metabolic syndrome which includes, obesity, fatty liver disease, type two diabodies

More information

tage Percent Total & over Total & over Men Women Men Women

tage Percent Total & over Total & over Men Women Men Women Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University

More information

The role of gut microbiome in IBS

The role of gut microbiome in IBS The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard

More information

FREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS

FREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS FREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS DR. ABDUL JABBAR, MBBS DR. ABDUL BASIT, MBBS DR. HAFIZ MUHAMMAD HANNAN AKBAR, MBBS ABSTRACT

More information

Fatty Liver Disease A growing epidemic

Fatty Liver Disease A growing epidemic Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences

More information

EFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS

EFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS 42 EFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS Prasong Tienboon MD, PhD. 1, Taned Chitapanarux MD. 2, Suwalee Pojchamarnwiputh MD. 3, Donrawee Leelarungrayub

More information

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY

More information

WORLDWIDE EPIDEMIOLOGY OF NASH

WORLDWIDE EPIDEMIOLOGY OF NASH WORLDWIDE EPIDEMIOLOGY OF NASH Stefano Bellentani, M.D., Ph.D. Chief of Gastroenterology and Hepatology Service Clinica Santa Chiara Locarno Switzerland & Fondazione Italiana Fegato (FIF), Bassovizza (Trieste),

More information

Accepted Article Preview: Published ahead of advance online publication

Accepted Article Preview: Published ahead of advance online publication Accepted Article Preview: Published ahead of advance online publication Omega-3 fatty acids prevent early-life antibiotic exposureinduced gut microbiota dysbiosis and later-life obesity K Kaliannan, B

More information

Dysbiosis & Inflammation

Dysbiosis & Inflammation MASTERING THE MICROBIOME: Dysbiosis & Inflammation 2017 Tom Fabian, PhD It is reasonable to propose that the composition of the microbiome and its activities are involved in most, if not all, of the biological

More information

Fatty Liver Disease OPSO Fall Conference 2018

Fatty Liver Disease OPSO Fall Conference 2018 Fatty Liver Disease OPSO Fall Conference 2018 Cynthia Worden, DO, MSHPE NAFLD Non-alcoholic fatty liver disease (NAFLD) is now considered to be the most common liver disease in the Western world and has

More information

ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,

ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total

More information

Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease

Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease ORIGINAL ARTICLE Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease Takashi Wada and Mikio Zeniya Abstract Objective We investigated the distribution and characteristics of the

More information

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human

More information

Metabolic Factors Frequency of Chocolate Consumption and Body Mass Index

Metabolic Factors Frequency of Chocolate Consumption and Body Mass Index School of Medicine, Health Sciences and Engineering Susquehanna Township High School Lecture Series Week 23, February 4 2014 Clinical Relevance of This Week s Topic Metabolic Factors Frequency of Chocolate

More information

Nutritional Issues In Advanced Liver Disease. Corrie Clark, RDN, LD

Nutritional Issues In Advanced Liver Disease. Corrie Clark, RDN, LD Nutritional Issues In Advanced Liver Disease Corrie Clark, RDN, LD Objectives List specific points to keep in mind when assessing the nutritional status of patients with advanced liver disease. Describe

More information

Fatty liver disease stages

Fatty liver disease stages Fatty liver disease stages Damage to the liver from excessive drinking can lead to ARLD. Years of alcohol abuse cause the liver to become inflamed and swollen. Physical exam If your liver is inflamed,

More information

The Role of Bacterial Products and Intestinal Microbiota in Non-Alcoholic Fatty Liver Disease

The Role of Bacterial Products and Intestinal Microbiota in Non-Alcoholic Fatty Liver Disease The Role of Bacterial Products and Intestinal Microbiota in Non-Alcoholic Fatty Liver Disease by Hannah Elizabeth Da Silva A thesis submitted in conformity with the requirements for the degree of Master

More information

FIBER HEALTH BENEFITS

FIBER HEALTH BENEFITS FIBER FIBER HEALTH BENEFITS Normal Laxation: Increase stool weight from fiber, water retained by fiber and bacterial mass Eases defecation and prevents or relieves constipation Cereal fibers are best;

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

NON-ALCOHOLIC FATTY LIVER DISEASE:

NON-ALCOHOLIC FATTY LIVER DISEASE: NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology

More information